ArticleBMC infectious diseases2025
T-cell activation of Toxoplasma gondii positive donors by maltodextrin nanoparticles formulated with killed Toxoplasma gondii.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nasal Nanoparticle Vaccine Induces a Cross-Strain T-Cell Immunity AgainstPharmaceutics · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nasal vaccination with killed tachyzoites from Toxoplasma gondii loaded in lipidated maltodextrin nanoparticles (NPL/T.gondii) has been shown to induce protection against lethal T.gondii infection in mice, sheep and squirrel monkeys. This protection was related to a unique T-cell mediated response (Th1 and Th17). In immunocompetent humans T.gondii infection is generally asymptomatic but leads to the formation of cysts in several organs. These cysts may reactivate during episodes of immunosuppression, owing to a Th1 immune exhaustion, leading to numerous complications. The objectives of the current study were to assess whether NPL/T. gondii vaccine can stimulate a specific IFN-γ secretion on peripheral blood mononuclear cells (PBMC) of Toxo-positive donors, in order to potentially prevent reactivation of the parasite. By using enzyme-linked immunospot (ELISpot) assays, the frequency of IFN-γ producing cells was quantified after 72 h of stimulation. This stimulation was specific of the Toxo + donors' memory T-cells. The uptake of this formulation by PBMCs was evaluated using flow cytometry, more particularly in T lymphocytes (CD3 + CD4 + and CD3 + CD8 +), B lymphocytes (CD3- CD19 +) and natural killer cells (CD3- CD56 +). Surprisingly, a lower antigen uptake was observed in all cell populations from Toxo + donors compared with the seronegative ones. Further in vitro analysis revealed that the early specific IFN-γ secretion by stimulated memory cells from Toxo-positive donors inhibited the endocytosis mechanism, therefore lowering their own vaccine uptake. These results suggest that NPL/T.gondii formulation can specifically trigger the existing Th1 immune response in positive donors, reinforcing their ability to control infection and reactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.